2.72
price up icon3.23%   0.085
after-market After Hours: 2.75 0.03 +1.10%
loading
Phio Pharmaceuticals Corp stock is traded at $2.72, with a volume of 40,126. It is up +3.23% in the last 24 hours and down -17.33% over the past month. Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
See More
Previous Close:
$2.635
Open:
$2.64
24h Volume:
40,126
Relative Volume:
0.61
Market Cap:
$2.87M
Revenue:
-
Net Income/Loss:
$-11.66M
P/E Ratio:
-0.2678
EPS:
-10.156
Net Cash Flow:
$-11.09M
1W Performance:
+10.12%
1M Performance:
-17.33%
6M Performance:
-59.64%
1Y Performance:
-69.31%
1-Day Range:
Value
$2.64
$2.80
1-Week Range:
Value
$2.4214
$2.80
52-Week Range:
Value
$2.1678
$18.81

Phio Pharmaceuticals Corp Stock (PHIO) Company Profile

Name
Name
Phio Pharmaceuticals Corp
Name
Phone
(508) 767-3861
Name
Address
11 APEX DRIVE, SUITE 300A, MARLBOROUGH, MA
Name
Employee
9
Name
Twitter
@phio_pharma
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
PHIO's Discussions on Twitter

Compare PHIO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PHIO
Phio Pharmaceuticals Corp
2.72 2.87M 0 -11.66M -11.09M -8.156
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
468.13 120.56B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
750.22 82.44B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
616.55 36.87B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
253.07 32.64B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
118.39 28.38B 3.30B -501.07M 1.03B -2.1146

Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-05-20 Initiated H.C. Wainwright Buy

Phio Pharmaceuticals Corp Stock (PHIO) Latest News

pulisher
Nov 19, 2024

Phio Pharmaceuticals Announces Completion of Enrollment in Second - The Kingston Whig-Standard

Nov 19, 2024
pulisher
Nov 19, 2024

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study - Newsfile

Nov 19, 2024
pulisher
Nov 15, 2024

Phio Pharmaceuticals Corp. (PHIO) Quarterly 10-Q Report - Quartzy

Nov 15, 2024
pulisher
Nov 14, 2024

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - Alberta Daily Herald Tribune

Nov 14, 2024
pulisher
Nov 14, 2024

Phio Pharma Reports 100% Tumor Clearance in Phase 1b Trial, Cuts Q3 Net Loss by 46% | PHIO Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

Phio Pharmaceuticals Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 14, 2024
pulisher
Nov 13, 2024

PHIO stock touches 52-week low at $2.38 amid market challenges - Investing.com

Nov 13, 2024
pulisher
Nov 08, 2024

Palantir Technologies Inc Cl A (PLTR-N) QuotePress Release - The Globe and Mail

Nov 08, 2024
pulisher
Nov 07, 2024

PHIOPhio Pharmaceuticals Corp. Latest Stock News & Market Updates - StockTitan

Nov 07, 2024
pulisher
Nov 07, 2024

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - Newsfile

Nov 07, 2024
pulisher
Nov 07, 2024

Phio Pharma's Cancer Drug Shows 100% Tumor Clearance in Clinical Trial | PHIO Stock | PHIO Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 01, 2024

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Quantisnow

Nov 01, 2024
pulisher
Oct 24, 2024

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th - Shoreline Beacon

Oct 24, 2024
pulisher
Oct 23, 2024

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile

Oct 23, 2024
pulisher
Oct 23, 2024

Financial Analysis: Dianthus Therapeutics (NASDAQ:DNTH) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World

Oct 23, 2024
pulisher
Oct 18, 2024

Nasdaq Financial 100 Index (IXF) QuotePress Release - The Globe and Mail

Oct 18, 2024
pulisher
Oct 18, 2024

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series - StockTitan

Oct 18, 2024
pulisher
Oct 16, 2024

Phio Pharmaceuticals presents novel cancer therapy data - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Phio Pharmaceuticals presents novel cancer therapy data By Investing.com - Investing.com South Africa

Oct 16, 2024
pulisher
Oct 16, 2024

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference - Newsfile

Oct 16, 2024
pulisher
Oct 08, 2024

Understanding the Risks of Investing in Phio Pharmaceuticals Corp (PHIO) - Knox Daily

Oct 08, 2024
pulisher
Oct 07, 2024

Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA - MSN

Oct 07, 2024
pulisher
Oct 07, 2024

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells - Newsfile

Oct 07, 2024
pulisher
Oct 05, 2024

Phio Pharmaceuticals (NASDAQ:PHIO) Shares Down 2.5% – Time to Sell? - Defense World

Oct 05, 2024
pulisher
Oct 01, 2024

Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer Conference - Yahoo Finance

Oct 01, 2024
pulisher
Sep 30, 2024

Nu Holdings Ltd Cl A (NU-N) QuotePress Release - The Globe and Mail

Sep 30, 2024
pulisher
Sep 25, 2024

This trade activity should not be overlooked: Hyliion Holdings Corporation (HYLN) - SETE News

Sep 25, 2024
pulisher
Sep 25, 2024

INTASYL Technology and Compounds to be Focus of Presentation at 20th - North Bay Nugget

Sep 25, 2024
pulisher
Sep 25, 2024

INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society - Newsfile

Sep 25, 2024
pulisher
Sep 25, 2024

HITE Hedge Asset Management LLC Sells 12,931 Shares of PHINIA Inc. (NYSE:PHIN) - MarketBeat

Sep 25, 2024
pulisher
Sep 25, 2024

Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail

Sep 25, 2024
pulisher
Sep 24, 2024

Hyliion Holdings Corporation (HYLN) Stock: A Comprehensive 52-Week Review - The InvestChronicle

Sep 24, 2024
pulisher
Sep 23, 2024

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 4% - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Financial Metrics Unveiled: P3 Health Partners Inc (PIII)’s Key Ratios in the Spotlight - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Does Hyliion Holdings Corporation (NYSE: HYLN) Still Need To Convince Analysts? - Stocks Register

Sep 23, 2024
pulisher
Sep 23, 2024

Barrow Hanley Mewhinney & Strauss LLC Purchases Shares of 898,419 Helios Technologies, Inc. (NASDAQ:HLIO) - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Hancock Whitney Corp Buys 10,920 Shares of PHINIA Inc. (NYSE:PHIN) - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

PHINIA Inc. (NYSE:PHIN) Shares Acquired by Long Road Investment Counsel LLC - Defense World

Sep 23, 2024
pulisher
Sep 22, 2024

King Luther Capital Management Corp Boosts Position in Helios Technologies, Inc. (NASDAQ:HLIO) - Defense World

Sep 22, 2024
pulisher
Sep 20, 2024

Texas Permanent School Fund Corp Has $1.39 Million Stock Holdings in PHINIA Inc. (NYSE:PHIN) - Defense World

Sep 20, 2024
pulisher
Sep 20, 2024

Thailand's new celebrity baby pygmy hippo, Moo Deng - The Business Standard

Sep 20, 2024
pulisher
Sep 18, 2024

Bokf Na Has $58,000 Stock Position in Haleon plc (NYSE:HLN) - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

American Century Companies Inc. Raises Position in PHINIA Inc. (NYSE:PHIN) - Defense World

Sep 18, 2024

Phio Pharmaceuticals Corp Stock (PHIO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.50
price up icon 1.61%
$74.59
price down icon 1.14%
$370.49
price down icon 2.02%
$43.06
price down icon 0.76%
$215.00
price up icon 4.29%
$118.39
price down icon 1.93%
Cap:     |  Volume (24h):